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to Identify and Study the Targets
of Bioactive Small Molecules
human diseases. FK506 and cyclosporin A (CsA) are
BSMs that are used in the clinic to inhibit graft rejection
in kidney transplant patients. Not surprisingly, these
molecules are potent inhibitors of T cell proliferation.
The modulatory effects of BSMs have also been har-
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2 Biotechnology and Genomics nessed for research purposes and have been invaluable
tools for probing complex biological networks and path-Pfizer Global Research and Development
Chesterfield, Missouri 63017 ways leading to seminal discoveries, protein function,
and protein-protein interactions. In the laboratory FK506
and CsA were instrumental in dissecting the component
steps of a central signaling cascade that caused activa-Natural and synthetic bioactive small molecules form
the backbone of modern therapeutics. These drugs tion of T cells [5]. Both drugs bind immunophilin (an
intracellular protein that binds immunosuppressiveprimarily exert their effect by targeting cellular host
or foreign proteins that are critical for the progression drugs) receptors, and the drug-receptor complexes in-
hibit calcineurin, a protein phosphatase that dephos-of disease. Therefore, a crucial step in the process of
recognizing valuable new drug leads is identification phorylates nuclear factor of activated T cells (NF-AT), a
transcription factor required for expression of interleu-of their protein targets; this is often a time consuming
and difficult task. This report is intended to provide kin-2 (IL-2) [6]. Compounds that are either too toxic or
that lack the appropriate pharmacological propertiesa comprehensive review of recent developments in
genetic and genomic approaches to overcome the for medicinal use can still be useful as research tools.
Wortmannin is a metabolite derived from the fungushurdle of discovering the protein targets of bioactive
small molecules. T. wortmanni. Wortmannin is renowned for the anti-
inflammatory and immunosuppressive effects it exerts
in experimental animals, but it has yet to advance as a
treatment for humans. Nonetheless, the use of wortman-Natural and Synthetic Bioactive Small Molecules
nin was a critical agent for elucidating the alternativeIn general, bioactive small molecules (BSMs) can be
roles that the PI3K (phosphatidylinositol 3-kinase) path-generated in two ways: these compounds are either
way plays in aspects of cellular and organismal physiol-extracted from living organisms or they are synthesized
ogy from growth and metabolism to cell survival, as wellby chemical means (examples of key BSMs are shown
as in disease mechanisms such as diabetes and can-in Figure 1). An abundance of organisms produces a
cer [7].diverse array of natural products, ranging from chemical
Millions of years of evolutionary selection have re-compounds to small peptides, some of which have bio-
sulted in naturally occurring BSMs that tightly controllogical activity. Perhaps the most widely known class
sophisticated intra- and intercellular regulatory net-of BSM is the antibiotic; a variety of antibiotics are made
works. However, many compounds with desirable prop-by microbes, plants, and marine organisms to fight off
erties are not amenable to large-scale production andmicrobial competitors or infectious agents. Rapamycin,
purification due technical constraints. Consequently,a macrolide antibiotic that was isolated from the filamen-
combinatorial chemistry and new organic chemical syn-tous bacterium S. hygroscopius that grows in the soil
thesis protocols are generally accepted as an alternateof Easter Island [1], is secreted from the bacterium and
method for producing large quantities of BSMs withinduces the starvation response (characterized by G0
diverse and complex structures [8]. With these methods,arrest and sporulation) in nearby fungi [2, 3], effectively
libraries composed of structurally distinct compoundsallowing S. hygroscopius to compete with fungi for lim-
can be synthesized and used to conduct meaningfulited soil nutrients. Natural BSMs are also produced as
target-specific or cell/organism-based phenotypic screens.chemical signals to control normal physiological pro-
The structural and chemical diversities of such com-cesses such as growth. For example, eukaryotic cells
pound libraries grant a high degree of assurance that asynthesize the phosphosphingolipid ceramide at ele-
compound that can exert a desired response in a cellvated levels, when stressed, to inhibit cell growth [4].
or on a protein will be present. One excellent exampleBoth natural and synthetic bioactive compounds can
of this is the miniaturized, whole-cell immunodetectionhave obvious medicinal value. Since the first natural
system called the cytoblot developed by Stockwell andproduct was isolated and chemically characterized, the
colleagues [9]. The cytoblot was designed for high-pharmacological properties of numerous compounds
throughput screening of a library bioactive compoundshave been described in animal models and in humans in
to isolate members that inhibited cell proliferation. Aclinical trials. BSMs with attractive therapeutic attributes
similar approach was used to identify monastrol, a novelare produced commercially and used to treat various
inhibitor of mitotic spindle bipolarity [10]. Like natural
products, the protein targets of synthetic BMSs are usu-
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Figure 2. A Comparison of Biochemical and Genetic Approaches
in the Identification of Targets of Bioactive Small Molecules
Figure 1. An Overview of Bioactive Small Molecules
Bioactive small molecules can be obtained as natural products from
bacteria, fungi, and plants, both from earth soil and sea. Living Chemical Genetics
organisms also produces a wide variety of small molecules as mes- Genetic manipulation and analysis became a corner-
sengers to relay signals within the cell or between cells. In recent stone of biological and biomedical research after com-
years, synthetic chemistry also produces large numbers of bioactive
parison of several gene sequences showed that thatsmall compounds that are used as therapeutics and chemical
many basic biological processes and important diseaseprobes to study biological processes.
pathways are conserved among species from yeast to
humans. Fundamental biological processes, including
apoptosis and the cell cycle, signaling pathways, metab-
Unmasking the Protein Targets of Bioactive
olism, transcription, translation, and control of cellular
Small Molecules
morphology have been described using genetics, as
To date, the vast majority of BSMs have been found to
have disease mechanisms such as cancer and diabetes.
interfere with protein function, although there are some
Various methods for genetic manipulation have become
chemical compounds that bind to nucleic acids and standard practice for identification of key genes. The
modulate their activity. Therefore, this review will focus term “forward genetics” describes a screen for an indi-
on the benefits and limitations of using chemical genet- vidual with a desired phenotype after a population of
ics and genomics to identify target proteins. Tradition- organisms is subjected to random mutation of their ge-
ally, protein targets have been isolated biochemically nomes. A “genetic modifier screen” illuminates genes
by using their affinity for their particular small-molecule that act in a specific pathway along with a gene of
ligands. Target proteins can be directly purified by their interest. This is based on the principle that mutations
affinity to chemical ligands. In this approach, chemical in two genes in the same pathway would “genetically
ligands are conjugated to a solid matrix, such as Sepha- interact” with each other, causing a more deleterious
rose, and then used as affinity columns to withdraw or enhanced phenotype, perhaps leading to synthetic
target proteins from cell or tissue extracts. This ap- lethality if the combined mutations cause death or, alter-
proach can be very effective and has led to the discovery natively, causing suppression of the phenotype associ-
of important drug targets such as calcineurin [5]. Varia- ated with the initial mutation alone. If a mutation is reces-
tions on this approach have also been developed, such sive or results in loss of function for a particular protein
as radioactively labeling the library compounds before product, the gene in question can be identified by intro-
screening protein-expression libraries and three-hybrid ducing the normal genetic counterpart into the mutant
systems for affinity-based screening [11]. However, af- strain compensating for the loss-of-function mutation,
finity purification does have shortcomings. A significant thereby producing a normal phenotype. In contrast,
pitfall lies in the availability of chemically reactive groups when the mutation has a dominant effect and affects
that can be used for crosslinking or radiolabeling. Even the physiology of the organism even in the presence of
when reactive groups are readily available to crosslink a normal copy of the gene, a library of genes must be
the compound to the solid matrix, the same groups may generated from the mutant strain and introduced into
be needed for binding and/or to inhibit the target protein the wild-type organism individually to identify the mutant
and, therefore, blocking with the solid support will ren- gene. More detailed information about chemical genet-
der the molecule inert. Another serious roadblock that ics can be found in two excellent recent reviews [12, 13].
many researchers face when using affinity purification is BSMs can replicate forward genetics and genetic
the high background often associated with this method, modifier screens (generating recessive, dominant, sup-
especially when the affinity between BSM ligand and pressive, enhancing, and synthetically lethal chemical
target protein is low. Recently, significant gains have mutations) by interfering with protein function, mimick-
been made in developing chemical genetic and chemical ing the effect of a mutation at the amino acid level.
genomic approaches to characterize BSM targets. A The workhorses of conventional genetics that are also
detailed comparison of biochemical and genetic ap- tenable for screening for drug targets include the bud-
ding yeast S. cerevisiae, the fission yeast S. pombe, theproaches is shown in Figure 2.
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ies were constructed from the rapamycin-resistant
strains and used to transform the wild-type yeast, lead-
ing to the identification of TOR1 and TOR2 [15, 16]. Tor1
and Tor2 are highly homologous, are phosphoinositol
kinase-related protein kinases (PIKKs), and are con-
served in mammals. Mutations at a conserved serine,
Ser-1972 in TOR1 or Ser-1975 in TOR2, confer dominant
rapamycin resistance [14–16]. Furthermore, TOR pro-
teins were shown to directly bind to a complex of
FKBP12-rapamycin (rapamycin binds to the peptidyl-
prolyl cis-trans isomerase FKBP12, resulting in a loss-
of-function phenotype) [17–19]. More importantly, the
serine mutations in the TOR proteins were mapped to
the rapamycin binding site and were shown to disrupt
binding of FKBP12-rapamycin to TOR proteins [19, 20].
Taken together, these observations unequivocally dem-
onstrate that TOR proteins are the physiological targets
of rapamycin. This example shows that drug-resistant
mutations in the drug target protein are dominant be-
cause they prevent drug-target binding. Belanger and
colleagues used the same principle to create a smart
polymerase chain reaction (PCR)-based strategy suit-
able for screening for the targets of many different drugs
in the pathogen S. pneumoniae [21]. This group gener-
ated a genomic library of S. pneumoniae in which ran-
dom mutations were created by using error-prone PCR.
The mutant library was then transformed back into the
Figure 3. Genetic Model Organisms and Genetic Screens for Tar-
wild-type bacterium, and the bacterial transformantsgets of Bioactive Small Molecules
were grown in the presence of a normally lethal drug. The
(A) Commonly used model organisms in identification and study of
PCR products would be expressed as mutant proteins indrug targets. Yeast (budding yeast and fission yeast) is an excellent
the bugs, and an arbitrary subset of organisms wouldmodel system to identify and study protein targets that are con-
be rendered drug-resistant by the presence of certainserved between fungi and animals. It is the most manipulatable
organism. The nematode and fruit fly are excellent multicellular or- polypeptides. Once a drug-resistant bacterium is sin-
ganisms. Zebrafish is increasingly used as a vertebrate model organ- gled out, the PCR-product conferring resistance can
ism. All of the organisms are tenable for large-scale genetic screens. be determined very rapidly, significantly simplifying the
While mouse is not suitable for genetic screens, as a small mammal, target identification process. The utility of this screen
it is closest to humans and is invaluable for genetic analysis of drug
was verified by using a number of known antibioticsactions.
including ciprofloxacin, fusidic acid, penicillin G, and(B) A flow chart of a typical genetic screen for targets of bioactive
spectinomycin, and the results confirmed some knownsmall molecules. Genetic approach is a powerful way to identify
and study the target of a bioactive small molecule. In a typical drug targets as well as identified several potential new
genetic analysis, the genome of an organism is randomly mutagen- drug targets. This approach should be expandable to
ized and screened for mutations that render drug resistance or other model organisms.
hypersensitivity. The drug-resistant and drug-sensitive genes can Alternatively, the protein targets of BSMs may bethen be isolated by complementation. Analysis of these genes may
studied by modulating the synthetic enzymes involved inprovide important clues to the drug target.
BSM biosynthesis in conjunction with a genetic modifier
screen. As mentioned earlier, ceramide is a eukaryotic
nematode worm C. elegans, the fruit fly D. melanogaster, sphingolipid with potent antiproliferative activity against
and the zebrafish D. rerio (Figure 3A). tumor cells and is generated by the sphingolipid bio-
Since small molecules mediate their effects on protein synthetic pathway. The small molecule ISP-1 is a newly
function by physical interaction, altering the small-mole- discovered immunosuppressant isolated from the fun-
cule binding sites would block this interaction, resulting gus I. sinclairii, which is a structural analog of sphingo-
in a drug-resistant phenotype. The fundamental require- sine; ISP-1 inhibits the synthesis of ketodihydrosphin-
ment for this interaction has been successfully exploited gosine, a precursor for ceramide and thus blocks
to screen and clone drug target proteins by using a ceramide production [22]. Sun and colleagues isolated
forward chemical genetic approach (a general strategy the gene YPK1/SLI2 as a multicopy suppressor of ISP-1-
is illustrated in Figure 3B) and is exemplified by the dependent cell proliferation [22]. Ypk1 acts downstream
discovery of the target of rapamycin (TOR). Rapamycin of Pkh1, a PDK1 (3-phosphoinositide dependent)-
is a small molecule that potently inhibits the growth of related yeast kinase. Phytosphingosine, a normal cellu-
budding yeast as well as human cells. To identify the lar derivative of ceramide, can directly activate Pkh1
target of rapamycin, the yeast genome was screened for [23], thereby leading to increased phosphorylation of
dominant rapamycin-resistant mutations that allowed Ypk1 [22]. The combined use of chemical genetics and
yeast to grow in the presence of rapamycin. Mutations traditional genetics used in this study demonstrated that
in two genetic alleles were discovered to permit cell Pkh1 is a biological target of ceramide-related sphingo-
lipids.growth in the presence of the drug [14]. Genomic librar-
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Confirmation of Candidate Target Proteins serine residue crucial for binding rapamycin is located
at the bottom of this pocket. Substitution of this serineBiochemical and chemical genetic approaches to iden-
tify BSM target proteins are complimentary. Biochemi- with a bulky amino acid such as threonine and isoleucine
prevents rapamycin to FRB due to steric hindrance,cal affinity purification typically suffers from contamina-
tion by nonspecific proteins, and it is important to resulting in dominant rapamycin resistance [19, 20, 32].
demonstrate that the purified proteins are physiologi-
cally relevant. If a small molecule inhibits a target pro-
The Mechanisms of Small-Molecule Actiontein’s activity, it should interfere with that protein’s cellu-
Genetics can also be used to discover the mechanismlar function, thus demonstrating the relevance of the
of action of small molecules. Brefeldin A is a fungaltarget proteins identified. Trapoxin is a microbially de-
metabolite of P. brefeldianum that inhibits Golgi-medi-rived cyclotetrapeptide that inhibits mammalian cell-
ated intracellular transport, leading to the disassemblycycle progression. mSin3 histone deacetylase (HDAC)
of the Golgi complex and redistribution of Golgi proteinsis found to bind to trapoxin in an affinity column [24].
to the endoplasmic reticulum [33]. Brefeldin A was firstTreatment of cells with trapoxin leads to changes in
shown to inhibit the guanine nucleotide exchange ofmSin3-depedent gene expression, indicating that mSin3
ADP-ribosylation factors (Arfs), a family of small GTPasesHDAC is the physiologically relevant target for tra-
required for the COP I coat assembly, biochemically inpoxin [25].
mammalian cells [34, 35]. Genetic studies in buddingThe commonly used strategy of “reverse genetics” is
yeast uncovered several brefeldin A-resistant alleles ofalso often used to verify purified target proteins. Reverse
the gene GEA1, a guanine nucleotide exchange factorgenetics refers to genetic manipulation of a known gene
(GEF) for Arf [36]. The brefeldin A-resistant mutationsto study its various roles. If a protein were the target of
were mapped to the Arf interaction region, suggestinga drug, certain mutations would mimic the drug effects.
that brefeldin A acts by preventing the Gea1 proteinOn the other hand, overexpression of the target gene
product from binding to Arf. Brefeldin A binds to Arfwould confer drug resistance, as in the case of campto-
noncompetitively, stabilizing the interaction of Arfs withthecin. This pentacyclic alkaloid isolated from the bark
its corresponding GEF and preventing the conversionof C. acuminata is potently toxic to cancer cells [26].
from Arf-GDP to Arf-GTP [36]. The abortive affect ofStudies in the 1970s showed that camptothecin is a
brefeldin A mimics a dominant-negative mutant of thesestrong inhibitor of nucleic acid synthesis; however, the
GEFs; thus, brefeldin A is effectively a more efficientcompound failed to inhibit purified DNA and RNA poly-
inhibitor than it would be by simply inhibiting Arf bindingmerases. Mammalian DNA topoisomerase (Top)I was
to its GEF [37]. Another good illustration of how thelater implicated as an intracellular target of campto-
mechanism of action of a small molecule was uncoveredthecin, since TopI could be crosslinked to the drug [27,
is demonstrated by rapamycin inhibition of TOR pro-28]. To definitively confirm that TopI is the camptothecin
teins. The FRB domain of TOR, the binding site fortarget in vivo, the yeast TOPI gene was identified and
FKBP12-rapamycin, is located just outside of the kinasedeleted. Deletion of TOPI was found to confer campto-
catalytic domain, suggesting that FKBP12-rapamycinthecin resistance, and overexpression of TopI causes
complex may directly inhibit TOR kinase activity or sim-camptothecin hypersensitivity, demonstrating that camp-
ply interfere with certain functions of TOR via anothertothecin inhibition indeed involves TopI [29, 30]. Geneti-
mechanism. In addition to the rapamycin-sensitive, es-cally identified drug targets also require independent
sential cell-cycle activity shared with Tor1, Tor2 has abiochemical confirmation because mutations in other
second essential but rapamycin-insensitive function incomponents of the drug target pathway may have addi-
actin cytoskeleton organization [19]. Although bothtional effects on drug sensitivity. For example, Tor1 and
functions require an intact Tor2 kinase domain, only theTor2 were initially hypothesized to act downstream of
cell cycle-related function is inhibited by rapamycin [19].the direct rapamycin target, since the dominant rapa-
This finding indicates that rapamycin is unlikely to actmycin-resistant mutations occur at a conserved serine
as an inhibitor of the kinase catalytic activity of Tor2,[16], and it was hypothesized that the serine mutations
which led researchers to speculate that FKBP12-rapa-mimicked the phosphorylation state, resulting in a con-
mycin could act by disrupting the interaction betweenstitutively active signaling pathway causing rapamycin
TOR and effector(s) key to cell cycle and, specifically,resistance [16]. However, as described earlier, chemical
G1 regulation [19]. Indeed, two recent reports indicatetechniques demonstrated a direct interaction between
that the interaction between mTOR and raptor, an mTORthe Tor proteins and the Frp1/FKBP12-rapamycin com-
cofactor, was disrupted by rapamycin [38, 39], providingplex [19]. Most significantly, the dominant rapamycin-
a direct experimental support to such model.resistant mutations at the conserved serine (Ser-1972
In addition to the gene encoding the direct drug target,in Tor1 and Ser-1975 in Tor2) were mapped to the Frp1/
mutations in genes in cellular pathways or processesFKBP12-rapamycin binding site and were shown to dis-
involving the drug target can often affect drug sensitiv-rupt the ability of Frp1/FKBP12-rapamycin to bind to
ity, enabling the use of BSMs as probes to tease apartTor1 and Tor2 [19]. Mammalian TOR (mTOR, also called
drug-sensitive pathways. A comprehensive understand-FRAP) was also isolated by FKBP12-rapamycin-affinity
ing of the drug pathways provides a detailed molecularpurification [17, 18]. Mammalian and yeast TOR proteins
profile of global drug effects, including previously unrec-share a conserved 11 kDa FKBP12-rapamycin-binding
ognized benefits and potential side effects, and may(FRB) domain [19, 20], which forms a four-helix-barrel
lead to improved therapeutic design and clinical proto-structure centered with a hydrophobic pocket in which
the lipophilic rapamycin is buried [31]. The conserved cols with fewer side effects. Global cellular analysis
Reviews
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showed that mTOR is a nutrient sensor, regulator of date targets of BSMs. Because the mammal closely
resembles humans, the mouse is an excellent geneticdiverse metabolic processes, and a component of the
insulin-signaling pathway. Treating cells with rapamycin model for human disease, and genetically engineered
mice that do not express a putative drug target gene orresults in cellular responses that are similar to those
observed under nutrient- and insulin-limitation condi- instead express a drug-resistant allele of the putative
target gene are important for confirming drug-target in-tions, suggesting that a potential side effect of rapa-
mycin is type 2 diabetes. Analysis of the global effects teractions and investigating the effects of disease-
related mutations. In addition, treatment of mutant miceof drugs on cells are also relevant when other biomacro-
molecules are the drug targets, such as DNA, RNA, and with drugs may help reveal additional targets for the
drugs. For instance, cyclooxygenases 1 and 2 (COX-1lipids. Bleomycin is an antitumor drug produced by
S. verticillus that produces DNA double-strand breaks, and COX-2) are enzymes required for prostaglandin (PG)
biosynthesis and are the targets of the widely used non-leading to the selective killing of cancer cells [40]. Ge-
netic analysis of cellular sensitivity to bleomycin and steroidal anti-inflammatory drugs (NSAIDS). COX-1- and
COX-2-deficient mice have been generated to evaluateother radiomimetic drugs, together with genetic re-
search on radiation sensitivity, reveals the presence of the individual roles of each isoform in the inflammatory
response [48]. COX-1 null mice showed an increase ina cellular network of enzymes controlling DNA damage
checkpoints and repair [41]. This and other similar find- PG concentration to about 25% above the wild-type
level, whereas the COX-2 null mice showed a decreaseings are leading to improvements in cancer radiation
and chemotherapeutics that are more effective in eradi- to 75% of the wild-type level, suggesting that COX-2 is
the major pathway for PG production during early stagescating cancerous cells while providing better protection
of normal cells. of inflammatory responses in this model.
Drugs can induce detoxification and occasionally im-
munological responses. Moreover, the effectiveness of
Genetic Analysis of Small-Molecule drugs can be affected by their in vivo stability and their
Targets in Animal Models ability to penetrate different tissues. These factors can
Yeast is a unicellular eukaryotic organism with a simple significantly affect phenotypes of animals treated with
genomic structure and therefore is an excellent system these compounds and analysis of mutant mouse phe-
to study the basic cell regulatory machinery. As a “mini- notypes can help predict the direct effects of small
mal” eukaryote, it has been a preferred system for the molecules or the indirect effect of target protein inhibi-
genetic analysis of drug targets and for elucidating tion. Calcineurin B (CnB) is the catalytic subunit of the
mechanisms of drug action. However, yeast lacks a reg- calcineurin phosphatase. A dominant-negative CnB
ulatory circuitry unique to multicellular organisms. For (CnB*/*) mouse was generated that showed a defect
drugs whose targets are only present in multicellular to remodel the primary vasculature to the structured
animals, more complex model systems such as the fruit pattern of the wild-type vasculature in the developing
fly and the nematode come into play. These models can embryos [49]. Injection of CsA, an inhibitor of cal-
be used to study more sophisticated phenotypes that cineurin, into pregnant mice between days 7.5 and 8.5,
involve cell-interaction and communication between dif- but not earlier or later, reproduced the exact vascular
ferent cell types, such as hormonal regulation, organ developmental defects seen in CnB*/* mice [49]. The
development and function, behavior, or motor activity. temporally selective action of CsA could not be due to
Both the fruit fly and the nematode have been used to degradation of the drug, failure of placental transfer, or
study the anesthetic halothane and related compounds embryonic metabolism of the drugs, since similar levels
[42–44]. Phenotypic and epistatic analyses suggest that of CsA were achieved during the critical period and after
volatile anesthetics interfere with the heterotrimeric G0 it. The observation that CsA administration mimics the
protein signal transduction pathway [45]. C. elegans has phenotype of the CnB*/* mutants indicates that in early
also been used to study the mechanism of action of the mammalian development, CsA is a highly specific inhibi-
antidepressant fluoxetine (Prozac). Various phenotypes tor of calcineurin function and is unlikely to have other
were observed upon fluoxetine that can be attributed developmentally critical targets.
to the effect of fluoxetine on serotonin reuptake, but
some additional phenotypes were observed in seroto-
nin-depleted worms, including altered neuromuscular Genomic Drug-Sensitivity Screens
The complete sequence of the human genome and manyactivity [46]. A genetic screen for fluoxetine-resistant
mutants led to identification of seven new genes. Analy- other genomes has been reported in the last few years.
Knowledge of the sequence of entire genomes has fun-sis of these mutants revealed a family of multi-panning
transmembrane proteins, which could be the fluoxetine damentally changed the landscape of biological and
biomedical research. Genomic and proteomic toolstargets resulting in the neuromuscular effect [46]. The
close evolutionary relationship between the fruit fly and such as large-scale gene knockouts, DNA, and protein
microarrays provide ways to systematically study genenematode with other insects and parasitic nematodes
also make them excellent model organisms to study and protein functions. Likewise, these new research
tools are being rapidly integrated into discovery andtargets of insecticides and antithelmics [47].
The mouse is too large and has a relatively slow repro- study of drug target proteins. After the completion of
genomic sequencing, efforts are being made to generateductive cycle to be useful as a model organism for
screening drug targets by using genetics. Nonetheless, systematic deletion mutants of model organisms such
as budding yeast, worms, fruit flies, and mice by usingmice can be effective as a genetic model to verify candi-
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Figure 4. Genomic Drug-Sensitivity Screens
Genomic deletion mutants using homologous
recombination or RNAi can be used directly
in drug-sensitivity screens. Mutation of drug
target genes or genes acting in the biological
pathways interfered with by bioactive small
molecules is known to alter drug sensitivity.
strategies from homologous recombination and trans- target, thereby allowing assessment of the global effects
of drugs on cells and organisms [55, 56]. Additionally,poson insertion to RNAi [50–54]. The Saccharomyces
Genome Deletion Project generated the first complete drug-sensitive gene products could be determining fac-
tors dictating the responses of certain diseases to spe-sets of deletion mutants of an organism [53]. Deletion
of target gene(s) confers drug resistance or hypersensi- cific therapies. Establishing a profile of drug sensitivity
genes, perhaps in cancer patients, could allow bettertivity, depending on the nature of the drug action, and
therefore the deletion mutants provide an exceptional prognosis of the outcome of chemotherapy.
opportunity for systematically identifying and studying
drug targets [55, 56] (Figure 4). Deletion mutants may DNA Microarrays in Small-Molecule
Target Researchbe arrayed and assayed for drug sensitivity on drug-
containing agar plates or assayed in liquid cultures in High-density oligonucleotide or complementary DNA
(cDNA) microarrays, collectively called DNA microar-multiwell plates [57]. High-throughput strategies for
such screens have recently been developed, such as rays, are used to simultaneously monitor expression of
genes in a genome [60]. DNA microarrays have beencell microarrays that were recently been created to ac-
commodate large numbers of samples in small surface extensively used to generate global gene expression
profiles under diverse cellular conditions, stress, andareas [58]. In addition, the yeast deletion mutants are
each tagged with a unique 20-base oligonucleotide se- stimulation with various extracellular stimuli. Changes in
global gene-expression profiles can provide importantquence [53, 59]. A high-density oligonucleotide microar-
ray recognizing the tag sequences has been generated clues about cellular processes and functions of relevant
genes. DNA microarrays have been shown to be usefulto analyze the relative abundance of individual deletion
strains in a cocktail of mutants in the presence of drugs. in the identification, validation, and study of small-mole-
cule targets. The immunosuppressive drugs FK506 andGiaever and colleagues conducted a proof-of-concept
study by using 233 heterozygous diploid strains to ex- cyclosporin A (CsA) inhibit calcineurin, a protein phos-
phatase critical for T cell signaling to regulate IL-2 ex-amine tunicamycin sensitivity through a haploinsuffi-
ciency approach [53]. They identified Alg7, an Asn-linked pression [5]. DNA microarray analysis showed that treat-
ment of a wild-type yeast strain with FK506 and CsAglycosyltransferase in yeast and a known tunicamycin
target. On the same note, our laboratory recently alters gene expression profiles that phenocopy those
caused by the null mutations of CNA1 and CNA2, thescreened the entire yeast deletion-mutant collections
for rapamycin sensitivity and found that both the tor1 calcineurin genes [61]. When FK506 was used at higher
concentration, a number of other genes were furthermutation in haploid yeast and the tor2 mutation in
heterozygous diploid yeast rendered the organism hy- induced independent of calcineurin [61]. These genes
are known to be regulated by the transcription factorpersensitive to rapamycin [57]. Pioneering studies like
those described above established the feasibility of us- Gcn4, suggesting that Gcn4 is a secondary target of
FK506. One of the difficulties associated with the DNAing genomic deletion mutants in drug target discovery.
Mutations in other genes in drug-sensitive pathways microarray approach is the scattered large amount of
unorganized data. To automate the data analytical pro-normally affect the host’s response to the drug, although
to a lesser degree than mutations in drug target genes. cess, Hughes and colleagues constructed a database
called a “compendium” of 300 expression profiles corre-Therefore, genomic deletion mutants are powerful for
systematically identifying pathways influenced by bio- sponding to diverse mutations and chemical treatments
of budding yeast [62] (Figure 5). By grouping expressionactive small molecules. Complete knowledge of all the
proteins sensitive to particular drug in an organism may profiles with similar patterns, they identified one gene,
YER044C, whose null mutation exhibits an expressionallow assembly of genetic pathways involving the drug
Reviews
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Figure 5. Gene Expression Profile-Based
Identification of Targets of Small Molecules
In a so-called compendium approach, A gene
expression profile of drug-treated cells is
compared to expression profiles of mutant
cells. A match of the expression profile of
drug-treated cells with one by gene mutation
would lead to a candidate drug target.
profile similar to mutations in ERG2, ERG3, and ERG11, Proteomic Approaches to Reveal
Small Molecule Targetscomponents of the ergosterol pathway. They therefore
named YER044C as ERG28 and demonstrated by gas Recent advances in the components of the proteome
of different organisms and technologies to detect thechromatography that erg28 mutant cells have an un-
usual ergosterol content in comparison to the wild-type identity of proteins have greatly facilitated discovery of
BSM protein targets. Proteins purified by drug-affinitycells, indicating that the Erg28 protein is a new compo-
nent in ergosterol metabolism. In a separate experiment, column can be readily identified by mass spectrometry
(MS) with very high sensitivity. Detailed information onthese authors discovered that the expression profile of
erg2 mutant was similar to that of the wild-type strain MS can be found in a recent review [64]. Furthermore,
protein microarrays or the protein chip has been fabri-treated with dyclonine, a topical anesthetic whose target
was unknown. Gas chromatography confirmed that cated by using the same concept as DNA microarray.
Like DNA microarray, distinct proteins in small quantitydyclonine treatment causes accumulation of fecosterol
in wild-type cells, indicating dyclonine inhibits Erg2, a are arrayed on microchips to generate protein microar-
rays [65, 66]. Protein chips have been successfully usedsterol C-8 isomerase. This appropriately named “rele-
vance network” approach was further developed to to identify protein kinase substrates [66] and antigens
[67], and they are also suitable for identifying drug tar-identify genes linked to anticancer drug susceptibility
[63]. Butte and colleagues generated expression profiles gets since they can be directly used to assay for the
binding of bioactive small molecules to a proteome arrayof 7245 genes in the NCI60 cells, a set of 60 different
human cancer cell lines compiled by the National Cancer (Figure 6). In a typical binding study, small chemicals
are labeled with color matrices and used to measureInstitute (NCI). In a separate study, a database of gene
expression profiles was generated for the same cancer affinity to thousands of proteins on a microchip [65].
After stringent washing, the proteins significantly la-cell lines treated with 5084 anticancer agents at half-
growth inhibitory concentration (GI50). By comparing beled by the chemicals will be identified by their posi-
tions on the chip. Theoretically, protein chips are per-the two databases, a network of genes was identified.
Changes in their expression levels may be linked to haps the most direct approach to identify drug targets
[68]; however, to provide an accurate representation ofcellular responses to a particular anticancer drug at
GI50. LCP1 is one of the genes that showed signifi- the cellular milieu, microarrays require sufficient repre-
sentation of purified recombinant proteins on a proteo-cant changes in response to the anticancer agent
NSC624044. LCP1 encodes L-plastin, an actin binding mic scale. A major difficulty for this technology is that
many eukaryotic proteins, especially proteins with largeprotein involved in leukocyte adhesion. Cells overex-
pressing LCP1 are found to have a higher GI50 for molecular weight, are difficult to produce in E. coli. On
the other hand, purification of native proteins or recom-NSC624044. Therefore, potential target proteins may
be identified by comparing the expression profiles of binant proteins from eukaryotic systems may be compli-
cated by the presence of copurified proteins in a com-defined mutants with that of cells treated with bioactive
small molecules. plex or of contaminating proteins. Therefore, while
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Figure 6. Protein Microarray in the Identifica-
tion of Drug Targets
Recombinant proteins are arrayed onto small
surface areas to generate protein microarray.
Fluorescence-labeled bioactive small mole-
cules are used to identify their target proteins
by their affinity.
protein microarrays hold perhaps the greatest promises, search. Genetic and genomic approaches to identify the
targets of these compounds are most effective whentheir practical use for drug target identification still
awaits technological improvements. used in conjunction with biochemical approaches. Can-
didate drug targets can be confirmed by their affinity to
the chemical compounds. On the other hand, proteinsConclusions
Bioactive small molecules have considerable value for found to bind certain drugs depend on chemical genetic
and genomic analyses to demonstrate their physiologi-therapeutic intervention and chemical biological re-
cal relevance of the drug’s effects. Target identification
is an important first step toward generating a molecular
understanding of the mechanism of drug action, the
therapeutic benefits, and side effects (Figure 7). This
also often leads to groundbreaking insights into biologi-
cal processes and pathways targeted by bioactive small
molecules, through which we can learn a great deal
about basic cell regulation, physiology, and disease
mechanisms. Such new knowledge can then be used
to discover new targets for developing better medicine.
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